Clinical Prognostic Factors of Renal Outcome in Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Glomerulonephritis in Elderly Patients
Overview
Nephrology
Affiliations
Background: The purpose of the present study was to determine clinical prognostic factors on renal survival in 37 older patients with antineutrophil cytoplasmic autoantibody-associated pauci-immune necrotizing crescentic glomerulonephritis (ANCA-associated GN) who underwent renal biopsy at our Department between January 1996 and December 2000.
Methods: The date of renal biopsy was used as the start date for entry into the study. Age, gender, 24 h proteinuria, serum creatinine level, blood pressure and ANCA were evaluated. The end-point for renal survival analysis was the start of chronic dialysis.
Results: Twenty-six (70%) patients showed varying degrees of renal insufficiency, nine (24%) patients required dialysis, 13 (35%) were hypertensive (BP > or =140/90 mmHg) and 33 (89%) had proteinuria. During follow-up (31.73+/-17.39 months), 16% of the patients (6/37) developed end-stage renal disease (ESRD). The actuarial renal survival rate for all patients was 92% at 1 year and 76% at 3 years, for Wegener's granulomatosis 80% at 1 and 3 years, for microscopic polyangiitis 85% at 1 and 3 years, and for renal limited disease (GN) 75% at 1 and 37% at 3 years. Age (P = 0.024), arterial hypertension (P = 0.018), proteinuria (P = 0.037) and serum cre-atinine > or =400 micro mol/l (P = 0.047) were the most important risk factors for ESRD.
Conclusion: The actuarial renal survival rate in elderly patients with ANCA-associated GN was 92% at 1 year and 76% at 3 years. Older age, arterial hypertension, proteinuria and serum creatinine > or =400 micro mol/l related to ESRD.
Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F, Xu L, Salas A, Wen Y, Eid S, Geetha D Clin Rheumatol. 2023; 42(9):2427-2435.
PMID: 37225927 PMC: 11128295. DOI: 10.1007/s10067-023-06644-2.
Long-term outcomes in elderly patients with ANCA-associated vasculitis.
McGovern D, Williams S, Parsons K, Farrah T, Gallacher P, Miller-Hodges E Rheumatology (Oxford). 2019; 59(5):1076-1083.
PMID: 31794032 PMC: 7671635. DOI: 10.1093/rheumatology/kez388.
[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].
Schirmer J, Aries P, Groot K, Hellmich B, Holle J, Kneitz C Z Rheumatol. 2017; 76(Suppl 3):77-104.
PMID: 29204681 DOI: 10.1007/s00393-017-0394-1.
Crnogorac M, Horvatic I, Toric L, Ljubanovic D, Tisljar M, Galesic K Int Urol Nephrol. 2017; 49(8):1419-1431.
PMID: 28646482 DOI: 10.1007/s11255-017-1610-2.
Hinojosa-Azaola A, Jimenez-Gonzalez A Clin Rheumatol. 2017; 36(9):1949-1957.
PMID: 28612242 DOI: 10.1007/s10067-017-3721-7.